Stay updated with breaking news from Public Issue. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Investors participated in the pre-IPO round include SBI Magnum Children's Benefit Fund, SBI Optimal Equity Fund, SBI Healthcare Opportunities Fund, Neuberger Berman Emerging Markets Equity Fund, Neuberger Berman Europe Holdings LLC and Neuberger Berman Strategic India Equity Master Fund Holdings Ltd.
Mumbai: Non-banking financial company (NBFC) Vivriti Capital Ltd on today announced its first public issue of non-convertible debentures (NCDs) on Friday (Aug 18) to raise up to Rs 500 crore.
The portion reserved for qualified institutional buyers (QIB) was subscribed 68 times, while the non-institutional investors' portion was subscribed 17 times. Retail investors bid for 3.78 times the shares set aside for them.
Ahmedabad-based Concord Biotech has fixed the price band at Rs 705 to Rs 741 per Equity Share for its maiden public offer. The initial public offering of the company will open on Friday, 4th August, 2023, for subscription and will close on Tuesday, 8th August 2023. Investors can bid for a minimum of 20 Equity Shares and in multiples of 20 Equity Shares thereafter, , Concord Biotech IPO, price band, stock exchange, pharma news
PFC NCD is a public issue of bonds. It is an investment opportunity for 3 years, 10 years and 15 years.